Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2016 - 2021)

Historic Long-Term Deferred Tax for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Q2 2021 value amounting to $345000.0.

  • Enanta Pharmaceuticals' Long-Term Deferred Tax fell 9774.35% to $345000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $345000.0, marking a year-over-year decrease of 9774.35%. This contributed to the annual value of $345000.0 for FY2020, which is 9695.79% down from last year.
  • As of Q2 2021, Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $345000.0, which was down 9774.35% from $345000.0 recorded in Q1 2021.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax peaked at $17.7 million during Q2 2017, and registered a low of $345000.0 during Q3 2020.
  • In the last 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax had a median value of $9.2 million in 2018 and averaged $8.5 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 20332.02% in 2017, then tumbled by 9774.35% in 2021.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $7.6 million in 2017, then increased by 22.2% to $9.2 million in 2018, then rose by 15.22% to $10.7 million in 2019, then tumbled by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
  • Its Long-Term Deferred Tax stands at $345000.0 for Q2 2021, versus $345000.0 for Q1 2021 and $345000.0 for Q4 2020.